As a Swiss life sciences company, a member of the Swiss Biotech Association and a leading preclinical CRO and organoid service innovator, we are delighted to once again be taking part in Swiss Biotech Day in Basel, one of the world's most important biotechnology conferences. The Swiss Biotech Day offers a valuable platform for knowledge exchange, innovation, and collaboration. We look forward to presenting our current initiatives, engaging in discussions about the future of biotech, and exploring new partnership opportunities. Visit us at the event and learn more about what drives our work. For more information about the Swiss Biotech Day, visit: swissbiotechday.ch

This week the FDA announced that it would phase out animal testing requirements for monoclonal antibodies and other drugs, citing the need for more effective, human-relevant screening methods. According to the Agency it will promote Human-Based Lab Models:

Back from BioEurope Spring 2025, the entire abc biopply team would like to take this opportunity to thank our customers, partners and friends in Milan for the exciting exchange and inspiring discussions. At the same time, a big thank you to our Korean friends from Preclina, with whom we were able to run the stand at the congress this year. We are already looking forward to meeting everyone again in Vienna in November.

Our experts will be onsite in Milan at BioEurope, booth #104 on level 0, alongside our partner CRO Preclina. We are eager to discuss your outsourcing needs and share insights on how we can support and accelerate your drug discovery programs. By introducing the cutting-edge technologies of abc biopply and Preclina as an integrated service package, we aim to enhance our offerings and provide even greater support for your research and drug development.

At abc biopply, we have already started preparing for this year's attendance at BioEurope Spring 2025 in Milan.We are happy to have our Research and Devepment Scientist Dr. Raquel Sousa joining us this year.

Solothurn, Switzerland and Seoul, Korea – abc biopply AG, a pioneer innovator of humanized multi-organoid disease models, and Preclina Inc., a preclinical contract research organization specializing in immune related disorders and humanized animal models, have announced a strategic collaboration. The partnership between the two companies will provide customers with end-to-end project planning on humanized preclinical models from early in vitro to in vivo studies and will revolutionize predictability in drug development.

We are proud to announce that abc biopply has officially been validated as a Biosafety Level 2 (BSL 2) Laboratory by the esteemed Waste Management and Operations Department of the Office for Waste, Water, Energy and Air of the Canton of Zurich on behalf of the Office for the Environment of the Canton of Zug.

Missed yesterday's webinar on "A New Tool in Regenerative Medicine: Employing 3D Cultures of Adipose Stromal Cells for Advanced Cartilage Repair "? Dive into the recording now for cutting-edge insights.

We are delighted to introduce Dr. Raquel Sousa as the newest addition to our abc biopply team. Dr. Sousa will be joining us as a Research and Development Scientist at our laboratory in Cham, starting on November 1st. Her expertise will strengthen our laboratory group, focusing on preclinical study projects and advancing our 3D assay portfolio. We are excitedly looking forward to the valuable contributions Dr. Sousa will make towards our organization's growth and success.

We are pleased to announce that abc biopply AG has joined the Swiss Biotech Association. As a member of the association, we are now part of a vibrant network of biotech professionals and companies in Switzerland.

The year 2023 is starting with positive news after the U.S. Congress passed the FDA Modernization Act 2.0, which removes the requirement for animal testing in drug development. The decision paves the way to finally allowing the use of data generated from new alternative methods (NAMs), such as abc biopply's 3D multi-organoid in chip assays.

We are pleased to welcome Dr. Olivera Evrova as a new member to our abc biopply team. Olivera will strengthen our laboratory group in the execution of preclinical study projects and the further development of our 3D assay portfolio.

abc biopply enjoyed a very successful participation at the Festival of Biologics 2022 in Basel, Switzerland. A big thank you to all our customers and potential partners for the enthusiastic feedback on our microphysiological preclinical disease models and assays. See you in San Diego.

Read the most recent article in DrugDiscovery online about abc biopply's activities.

20.08.2022 Seattle/Solothurn Seattle-based primary cell biology CRO ReachBio and Swiss biotech abc biopply announced today a partnership to jointly co-market their preclinical test models. The two companies plan to support their clients with an even more predictive assay portfolio to further increase the efficiency of their drug discovery and development services.

In collaboration with the American Physiological Society (APS) and our American partner nanoscaleLABS, abc biopply is organizing a webinar on the use of 3D CoSeedis™ in high throughput ex vivo propagation of multiple myeloma cells. Dr Johannes Waldschmidt and Dr Andreas Thomsen from the University of Freiburg in Germany together with Dr Marco Leu from abc biopply will discuss the importance of reliable 3D preclinical disease models in accurate and predictive compound testing.

Solothurn 08.02.2022 Swiss Biotech Company abc biopply reports revenues in 2021 more than doubled in its core business with its preclinical 3D tumor models. The company has started offering these specialized CRO services to its biotech and pharma clients since 2019.

abc biopply and SEED Bioscienses have recently started to co-develop an inovative new method to make 3D cell cultures assessible for HTS applications. In this collaboration, abc biopply provides highly homogenous and uniform 3D cultures in large quantities using its prorietary 3D CoSeedis™ platform whereas SEED Bioscienses uses its DISPENCELL technology to disperse them into HTS compatible multi-well plates. Finally, HTS users will gain access to a reliable source of high quality 3D cultures in sufficient quantities to reach unprecedented efficacy in HTS of 3D cultures.

We are very pleased to be one of the key players mentioned in the most recent 3D cell culture market report of IndustryARC.

Find the article about abc biopply on the startupticker.ch platform from 11.03.2021

3D CoSeedis™ is now also available in the United States.

abc biopply enters into a strategic partnership with Quadira Biosciences, to create a sustainable concept for the development of highly effective therapeutic antibodies without animal testing.

Cooperation of abc biopply with CELLdynamics demonstrates that 3D CoSeedis™ outperforms conventional 3D cell culture systems in generating highly homogenous and uniform spheroids.

Welcome to Chayon Laboratories – our new partner in Korea.

3D CoSeedis™ has been recommended as the tool of choice in the production of extracellular vesicles (EV) from 3D cultures. The chapter in Methods in Enzymology gives a detailed introduction into the isolation of EVs from highly homogenous and uniform 3D cultures using the 3D CoSeedis™ system.

Our international distribution network expands.

Sign up for the next webinar about the latest news about 3D CoSeedis™.

A new white paper is available.

The webinar with our medical advisor Dr. Andreas Thomsen takes place on 14 May 2020.

3D CoSeedis™: the ideal 3D model to grow primary cells.

After many fruitful conversations in the USA we return home with a huge suitcase full of helpful information.

Visit our symposium on Tuesday, 12 November in Berlin.

3D CoSeedis™ goes 24! Have a look at our new format of the 3D cell co-culture system.

Thank you to our partners.

Special thanks to our Medical Advisor and Regina Rufener.

abc biopply goes to the UK:. Thistle Scientific becomes abc biopply’s distribution partner in the UK.

Meet us at ILMAC in Basel

The method can perform fluorescent based viability/cytotoxicity tests on spheroidal and non-spheroidal 3D constructs.

The authors made use of the 3D CoSeedis™ system to assess radiation resistance in 3D conditions via a colony forming assay (CFA).

A new publication on the colony forming assay in cancer research is available.

The sales team of BioConcept, our partner in Switzerland, visited us and attended a training day about 3D CoSeedis™.

The talk about the unique microenvironments in 3D models has been a great success.

Our product family is growing.

The symposium was a complete success.

Visit the symposium in Munich on 27 March 2019.

Visit us on 5 February 2019 in France and learn more about 3D CoSeedis™.

3D CoSeedis™ has recently been used in a study on extracellular vesicle composition.

3D CoSeedis™ is now available in Germany, Austria, France and Canada.

A new publication about 3D CoSeedis™ is available.

abc biopply has developed a standardised way to conveniently embed 3D cell aggregates grown in the 3D CoSeedis™ matrix in paraffin for immunological analysis. In this context we haverecently also started a partnership with AnaPath.

abc biopply is introducing a fully standardised 3D micro-tumour system based on its 3D CoSeedis™ technology platform.

abc biopply launches a new 3D CoSeedis™ system in June.

Visit us at our booth E2 at the DECHEMA 3D Cell Culture Congress in Freiburg (DE)

Learn more about 3D CoSeedis™ and ask the experts directly.

We have received attention in various newspapers.